Core Insights - Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, published a peer-reviewed research article analyzing biomarkers in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study focuses on two biomarkers, DNMT3A and GMPS, and their prognostic significance, which is influenced by immune composition, metabolic reprogramming, and innate immune sensing pathways [2] - The analysis integrated data from over 7,000 patients, highlighting the context-dependent nature of these biomarkers [2] Group 2: Educational Mission - The Brush and Key Foundation aims to mentor young scholars through hands-on research experiences, fostering critical thinking and professional development [3][5] - The publication reflects the foundation's commitment to bridging scientific inquiry with real-world research experience [3][5] Group 3: Author Insights - Dr. Drashya Shah, an intern supported by the Brush and Key Foundation, emphasized the value of mentorship in enhancing research quality and personal confidence [4] - Dr. Vuong Trieu noted the intersection of bioinformatics, translational oncology, and mentorship in generating scientific insights [4] - Dr. Wen-Han Chang highlighted the importance of considering tumor context when interpreting biomarkers [4] Group 4: Company Background - Oncotelic Therapeutics, originally founded as OXiGENE, Inc. in 1988, focuses on oncology drug development, particularly for rare pediatric cancers [6] - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is involved in developing treatments for various cancers and conditions, including Parkinson's Disease and erectile dysfunction [6][7][8]

Core Insights - Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, published a peer-reviewed research article analyzing biomarkers in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) [1][2] Group 1: Research Findings - The study focuses on two biomarkers, DNMT3A and GMPS, and their prognostic significance in HCC and PDAC, highlighting that their relevance is context-dependent, influenced by immune composition and metabolic pathways [2] - The research integrates data from over 7,000 patients, providing a comprehensive analysis of survival outcomes and tumor microenvironment [2] Group 2: Educational Mission - The Brush and Key Foundation aims to mentor young scholars through hands-on research experiences, fostering critical thinking and professional development [3][5] - The collaborative environment of the foundation enhances the quality of research and builds confidence in young researchers [4] Group 3: Company Background - Oncotelic Therapeutics, established in 1988, focuses on oncology drug development, particularly for rare pediatric cancers and other malignancies [6] - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is developing treatments for various conditions, including Parkinson's Disease and erectile dysfunction [7][8]

Core Insights - Oncotelic Therapeutics, Inc. has made significant clinical progress and regulatory validation over the past two years, highlighting its potential in oncology and immunotherapy treatments [1][3] Company Overview - Oncotelic is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, aiming to address high unmet medical needs in cancers and rare pediatric indications [4] - The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents [5] Pipeline and Programs - Oncotelic's pipeline includes multiple late-stage programs targeting oncology and rare diseases, with significant clinical milestones achieved [2][3] - Key drug candidates include: - OT-101 (TGF-β inhibitor): Phase 3 for pancreatic cancer, with additional applications in ARDS/COVID-19 [8] - OXi4503 (vascular disrupting agent): Phase 2 in AML/MDS, advancing toward pivotal phase 3 design [8] - CA4P / Fosbretabulin: Late-stage oncology asset currently under repositioning [8] - AL-101 (intranasal apomorphine): Phase 2 for Parkinson's disease and sexual dysfunctions [8] - AL-102 (oligonucleotide antisense via intrathecal injection): Discovery stage for Alzheimer's disease [8] - Pediatric Rare Disease Programs: Targeting orphan indications with potential for Priority Review Vouchers (PRVs) [8] - Nanomedicine Pipeline: Advancing multiple 505(b)(2) drug candidates into clinical testing, leveraging a faster and more cost-efficient route to market approval [8]